Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 11Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Head and Neck Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasms 5Colorectal Neoplasms 5Advanced Solid Tumor 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Solid Tumor 3Small Cell Lung Carcinoma 3Recurrence 3Rectal Neoplasms 3Nasopharyngeal Neoplasms 3Turcot syndrome 2Sarcoma 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Microsatellite Stable Metastatic Colorectal Cancer 2Locally Advanced Rectal Cancer 2Liposarcoma 2Laryngeal Neoplasms 2Gestational Trophoblastic Disease 2Esophageal Neoplasms 2

Interventions

toripalimab 1Injections 1Clinical Trials, Phase II as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Malignant Solid Tumors × toripalimab × Clear all
NCT07480733 2026-05-29

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
410 enrolled
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡